Features June 2016 Issue

New Drug Improves Cholesterol, but Doesn’t Lower Heart Risks

A Cleveland Clinc study finds that evacetrapib lowers LDL and raises HDL, yet heart attack and stroke rates are unchanged among patients on the drug.

Despite its ability to reduce LDL (“bad”) cholesterol and significantly increase levels of HDL (“good”) cholesterol, the experimental medication evacetrapib failed to reduce rates of major cardiovascular events, such as heart attack and stroke.

To continue reading this article you must be a paid subscriber.

Subscribe to Heart Advisor

Get the next year of HEART ADVISOR for just $20. That's a savings of $19 off the regular rate.

With your paid subscription you will receive unlimited access to all of our online content. That is over a decade of previous issues from Cleveland Clinic, the hospital rated #1 in cardiac care by U.S. News & World Report - free of charge.

Subscriber Log In

Forgot your password? Click Here.

Already subscribe but haven't registered for all the benefits of the website? Click here.